AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2525330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (30 mg)
Number of subjects: 12
Study 2525330 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 12
Study 2525330 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (low-dose 60 mg)
Number of subjects: 12
Study 2525330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2525330 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (high-dose 120 mg)
Number of subjects: 12
Study 31463484 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vertical internal mattress sutures
Number of subjects: 48
Study 31463484 — intervention group
Group type: COMPARATOR
Intervention: Simple loop interrupted sutures
Number of subjects: 48
Study 28095801 — intervention group
Group type: EXPERIMENTAL
Intervention: Small‐quantity lipid‐based nutrient supplement (SQ‐LNS)
Number of subjects: 0
Study 28095801 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN)
Number of subjects: 0
Study 28095801 — intervention group
Group type: COMPARATOR
Intervention: Iron & folic acid (IFA)
Number of subjects: 0
Study 28095801 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ‐LNS
Number of subjects: 0
Study 28095801 — intervention group
Group type: COMPARATOR
Intervention: MMN
Number of subjects: 0
Study 28095801 — intervention group
Group type: COMPARATOR
Intervention: IFA
Number of subjects: 0
Study 26248034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications (diet and exercise) and intensive glycemic control
Number of subjects: 83
Study 26248034 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil citrate® 100 mg for 2-3 times per week in addition to intensive glycemic control
Number of subjects: 83
Study 23868156 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated WM lesion segmentation using the Lesion Segmentation Toolbox
Number of subjects: 50
Study 23868156 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated WM lesion segmentation using the Lesion Segmentation Toolbox at k = 0.25
Number of subjects: 50
Study 23868156 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective WM lesion segmentation
Number of subjects: 50
Study 21269294 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term ketogenic diet (8 months)
Number of subjects: 40
Study 21269294 — intervention group
Group type: COMPARATOR
Intervention: Long-term ketogenic diet (> 2 years)
Number of subjects: 40
Study 19756419 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 24-h infusion of 100 mg/kg per day ceftazidime
Number of subjects: 56
Study 19756419 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily dosing of 200 mg/kg per day ceftazidime
Number of subjects: 56
Study 16954547 — intervention group
Group type: EXPERIMENTAL
Intervention: No evidence of diabetes
Number of subjects: 22
Study 16954547 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 22
Study 15063387 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg lycopene/day (Group A)
Number of subjects: 58
Study 15063387 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg lycopene/day (Group B)
Number of subjects: 58
Study 15063387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 58
Study 11772139 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha-2a (40 kD) 180 microg/week
Number of subjects: 0
Study 11772139 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon-alpha-2a (40 kD)
Number of subjects: 0
Study 9228499 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 35
Study 9228499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 8233297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 342
Study 8233297 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 342
Study 2423799 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin added to HCTZ
Number of subjects: 209
Study 2423799 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin added to HCTZ
Number of subjects: 209
Study 2423799 — intervention group
Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 209
Study 29530495 — intervention group
Group type: EXPERIMENTAL
Intervention: GA-driven intervention
Number of subjects: 40
Study 29530495 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 27647710 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG)
Number of subjects: 158
Study 27647710 — intervention group
Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC)
Number of subjects: 158
Study 23686394 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizon stabilization software
Number of subjects: 18
Study 23686394 — intervention group
Group type: COMPARATOR
Intervention: No horizon stabilization
Number of subjects: 18
Study 22496538 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance exercise program (3 times/week; three sets, six to eight repetitions at 75%-80% of one-repetition maximum)
Number of subjects: 237
Study 22496538 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance exercise program
Number of subjects: 237
Study 20888262 — intervention group
Group type: COMPARATOR
Intervention: Backpack repair
Number of subjects: 10
Study 20888262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Row repair
Number of subjects: 10
Study 17914351 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible dialysis solutions (B)
Number of subjects: 93
Study 17914351 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis solutions (S)
Number of subjects: 93
Study 16157429 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland)
Number of subjects: 303
Study 16157429 — intervention group
Group type: COMPARATOR
Intervention: No vaccination
Number of subjects: 303
Study 14566313 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin ophthalmic solution
Number of subjects: 167
Study 14566313 — intervention group
Group type: COMPARATOR
Intervention: 0.3% ofloxacin
Number of subjects: 167
Study 14566313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 10751698 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn injury group
Number of subjects: 40
Study 10751698 — intervention group
Group type: COMPARATOR
Intervention: Fracture group
Number of subjects: 40
Study 10751698 — intervention group
Group type: COMPARATOR
Intervention: Non ill/injured group
Number of subjects: 40
Study 8981915 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH; 2.0 IU/d)
Number of subjects: 30
Study 8981915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1536016 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml (2.0 mg) of chymopapain
Number of subjects: 30
Study 1536016 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 ml (8.0 mg) of chymopapain
Number of subjects: 30
Study 1536016 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml (2.0 mg) of chymopapain and 2.0 ml (8.0 mg) of chymopapain
Number of subjects: 30
Study 6342219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maintenance dose of prednisone (30 mg/day) and antilymphocyte globulin (ALG)
Number of subjects: 23
Study 6342219 — intervention group
Group type: COMPARATOR
Intervention: High maintenance doses of prednisone (2 mg/kg/day with tapering) and intravenous methylprednisolone (IVMP)
Number of subjects: 23
Study 6342219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maintenance dose of prednisone (30 mg/day)
Number of subjects: 23
Study 6342219 — intervention group
Group type: COMPARATOR
Intervention: High maintenance doses of prednisone (2 mg/kg/day with tapering)
Number of subjects: 23
Study 31971914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure on P6 (Neiguan) point
Number of subjects: 82
Study 31971914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure on KID21 (Youmen) point
Number of subjects: 82
Study 31971914 — intervention group
Group type: COMPARATOR
Intervention: Both P6 and KID21 pressure groups
Number of subjects: 82
Study 31138134 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (with and without anidulafungin)
Number of subjects: 395
Study 31138134 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-confirmed invasive aspergillosis)
Number of subjects: 395
Study 29228935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 2.0% morphine
Number of subjects: 11
Study 29228935 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 11
Study 25307409 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type-A (BoNT‐A)
Number of subjects: 60
Study 25307409 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study 24151217 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording 20-26 words per day
Number of subjects: 549
Study 24151217 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording 27-33 words per day
Number of subjects: 549
Study 24151217 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording ≥34 words per day
Number of subjects: 549
Study 24151217 — intervention group
Group type: COMPARATOR
Intervention: Recording <20 words per day
Number of subjects: 549
Study 22866290 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival grafts (FGG group)
Number of subjects: 64
Study 22866290 — intervention group
Group type: COMPARATOR
Intervention: Vestibuloplasty (VP group)
Number of subjects: 64
Study 19407955 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy combined with composite salvia injection (CSI)
Number of subjects: 150
Study 19407955 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 150
Study 17406813 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame-based liquids
Number of subjects: 51
Study 17406813 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-based liquids
Number of subjects: 51
Study 15107411 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Number of subjects: 16
Study 15107411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 16
Study 11179128 — intervention group
Group type: EXPERIMENTAL
Intervention: NAECC criteria
Number of subjects: 118
Study 11179128 — intervention group
Group type: EXPERIMENTAL
Intervention: LISS criteria
Number of subjects: 118
Study 11179128 — intervention group
Group type: COMPARATOR
Intervention: NAECC vs LISS
Number of subjects: 118
Study 9568649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative abdominal cavity culture obtained in group A (30.1%)
Number of subjects: 499
Study 9568649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative abdominal cavity culture obtained in group B (67.1%)
Number of subjects: 499
Study 9568649 — intervention group
Group type: COMPARATOR
Intervention: Single antibiotic agent treatment in group A
Number of subjects: 499
Study 9568649 — intervention group
Group type: COMPARATOR
Intervention: Triple-agent antibiotics in group B
Number of subjects: 499
Study 8041524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 0
Study 8041524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of spatula and Cytobrush
Number of subjects: 0
Study 8041524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of spatula and swab
Number of subjects: 0
Study 8041524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervex brush alone
Number of subjects: 0
Study 8041524 — intervention group
Group type: COMPARATOR
Intervention: All methods
Number of subjects: 0
Study 3045271 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 231
Study 3045271 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 231
Study 31160252 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28938473 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 12 weeks
Number of subjects: 32
Study 28938473 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control subjects
Number of subjects: 32
Study 26151244 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey associated with dodder seed extract
Number of subjects: 52
Study 26151244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23973504 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous conditioned plasma (ACP)
Number of subjects: 54
Study 23973504 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 54
Study 23973504 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 54
Study 21595877 — intervention group
Group type: COMPARATOR
Intervention: Systematic program for increasing influenza vaccine uptake among HCWs
Number of subjects: 0
Study 19084800 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation (CPVA, group 1, n = 47)
Number of subjects: 144
Study 19084800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI, group 2, n = 48)
Number of subjects: 144
Study 19084800 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid strategy combining CFAE ablation and PVAI (CFAE + PVAI, group 3, n = 49)
Number of subjects: 144
Study 17154782 — intervention group
Group type: EXPERIMENTAL
Intervention: Object substitution masking (OSM)
Number of subjects: 0
Study 12701008 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclipping
Number of subjects: 32
Study 12701008 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic epinephrine injection therapy
Number of subjects: 32
Study 12701008 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclipping for gastric body Dieulafoy lesions
Number of subjects: 32
Study 12701008 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic epinephrine injection therapy for gastric body Dieulafoy lesions
Number of subjects: 32
Study 10764298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (0.4 ml, 3,800 AXa IU or 0.6 ml, 5,700 AXa IU)
Number of subjects: 223
Study 10764298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 10764298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 223
Study 9363412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (maximum daily dose: 1.6 mg)
Number of subjects: 80
Study 9363412 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (maximum daily dose: 0.6 mg)
Number of subjects: 80
Study 9363412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 80
Study 9363412 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 80
Study 9363412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine and Clonidine
Number of subjects: 80
Study 1582811 — intervention group
Group type: EXPERIMENTAL
Intervention: New Aniseikonia Test (NAT)
Number of subjects: 19
Study 1582811 — intervention group
Group type: COMPARATOR
Intervention: Space Eikonometer
Number of subjects: 19
Study 1582811 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-video simulation of NAT
Number of subjects: 19
Study 3157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal computerized tomography (CT) performed initially in group I patients.
Number of subjects: 36
Study 3157936 — intervention group
Group type: COMPARATOR
Intervention: Conventional examinations (including 20 invasive) performed in a definite order in group II patients.
Number of subjects: 36
Study 3157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal computerized tomography (CT) performed in group I patients.
Number of subjects: 36
Study 3157936 — intervention group
Group type: COMPARATOR
Intervention: Conventional examinations performed in group II patients.
Number of subjects: 36
Study 3157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal computerized tomography (CT) if performed early in all patients.
Number of subjects: 36
Study 30736383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangiferin + Luteolin (PHE: 50 mg/day; MLE: 140 mg/day)
Number of subjects: 12
Study 30736383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangiferin + Luteolin (PHE: 100 mg/day; MLE: 420 mg/day)
Number of subjects: 12
Study 30736383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28920491 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriber communication behaviors (facilitation, rapport, procedural, psychosocial, biomedical, total utterances)
Number of subjects: 175
Study 28920491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of prescriber to consumer utterances
Number of subjects: 175
Study 26775275 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned rotational atherectomy (RA)
Number of subjects: 667
Study 26775275 — intervention group
Group type: COMPARATOR
Intervention: Provisional rotational atherectomy (RA)
Number of subjects: 667
Study 23902933 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care (CGC)
Number of subjects: 397
Study 23902933 — intervention group
Group type: COMPARATOR
Intervention: Orthopedic care (OC)
Number of subjects: 397
Study 22648467 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training Men (RTM)
Number of subjects: 50
Study 22648467 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training Women (RTW)
Number of subjects: 50
Study 22648467 — intervention group
Group type: COMPARATOR
Intervention: Control Group Men (CGM)
Number of subjects: 50
Study 22648467 — intervention group
Group type: COMPARATOR
Intervention: Control Group Women (CGW)
Number of subjects: 50
Study 19321507 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Controlled Ventilation (VCV)
Number of subjects: 109
Study 19321507 — intervention group
Group type: COMPARATOR
Intervention: Pressure Limited Ventilation (PLV)
Number of subjects: 109
Study 16732060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (ICRT) with 17 Gy
Number of subjects: 336
Study 16732060 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary radiation therapy (ICRT) with 14 Gy
Number of subjects: 336
Study 12687820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sensor DDDR pacemakers during CAEP test
Number of subjects: 25
Study 12687820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sensor DDDR pacemakers during Harbor test
Number of subjects: 25
Study 12687820 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group during CAEP test
Number of subjects: 25
Study 12687820 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group during Harbor test
Number of subjects: 25
Study 12687820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sensor DDDR pacemakers
Number of subjects: 25
Study 10737151 — intervention group
Group type: EXPERIMENTAL
Intervention: Two active bars/day
Number of subjects: 41
Study 10737151 — intervention group
Group type: EXPERIMENTAL
Intervention: One active bar/day
Number of subjects: 41
Study 10737151 — intervention group
Group type: COMPARATOR
Intervention: Placebo groups (one active and one placebo bar, and two placebo bars per day)
Number of subjects: 41
Study 10737151 — intervention group
Group type: EXPERIMENTAL
Intervention: General and emotional/social functioning components of SF-36
Number of subjects: 41
Study 9372298 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hand in left space
Number of subjects: 0
Study 9372298 — intervention group
Group type: COMPARATOR
Intervention: Right hand in right space
Number of subjects: 0
Study 1351673 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) with Triazolam (0.250 mg)
Number of subjects: 0
Study 1351673 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) with Zopiclone (7.5 mg)
Number of subjects: 0
Study 1351673 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Triazolam (0.250 mg)
Number of subjects: 0
Study 1351673 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Zopiclone (7.5 mg)
Number of subjects: 0
Study 3985085 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (diuretic)
Number of subjects: 11
Study 31493783 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (MEmind) for ecological momentary assessment (EMA) data capture related to sleep, appetite, and suicide ideations.
Number of subjects: 0
Study 30469433 — intervention group
Group type: EXPERIMENTAL
Intervention: hypothermic histidine‐tryptophan‐ketoglutarate (HTK) solution
Number of subjects: 90
Study 30469433 — intervention group
Group type: EXPERIMENTAL
Intervention: normothermic oxygenated blood
Number of subjects: 90
Study 30469433 — intervention group
Group type: COMPARATOR
Intervention: standard CPB with no pulmonary perfusion
Number of subjects: 90
Study 27228959 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible fibrescope
Number of subjects: 40
Study 27228959 — intervention group
Group type: COMPARATOR
Intervention: Pentax Airway Scope
Number of subjects: 40
Study 24849441 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI (98 lesions)
Number of subjects: 226
Study 24849441 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI (101 lesions)
Number of subjects: 226
Study 24849441 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (medication group, 94 lesions)
Number of subjects: 226
Study 22595272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs), artemether-lumefantrine (AL), amoxicillin
Number of subjects: 1017
Study 19019358 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g two times per day, n = 36)
Number of subjects: 66
Study 19019358 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pill (OCP) (35 microg ethinyl E(2)‐2 mg cyproterone acetate, n = 30)
Number of subjects: 66
Study 18654759 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 280
Study 18654759 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 280
Study 15825788 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastomeric rings
Number of subjects: 21